(Cannabidiol + dronabinol) is under clinical development by MGC Pharmaceuticals and currently in Phase III for Sedation. According to GlobalData, Phase III drugs for Sedation have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Cannabidiol + dronabinol)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cannabidiol + dronabinol) overview
CannEpil, a fixed-dose combination of tetrahydrocannabinol (THC) and cannabinoid (CBD) is under development for the treatment of refractory epilepsy, driving performance, sedation and mood. It is administered by sublingual route as oil solution. The drug candidate acts by targeting cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).
MGC Pharmaceuticals overview
MGC Pharmaceuticals is a medical cannabis company. It carries out the development and supply of non-psychoactive cannabidiol (CBD) resin. The company’s product catalog includes CannEpill, CannEKids, TopiCann, Tetrinol, CogniCann, CannaSom and active pharmaceutical ingredients (API). It products find usage in the treatment of Refractory Epilepsy, Anti-inflammatory topical treatment, Cachexia, Dementia and Insomnia. It has partnerships with global distributors, prominent universities, academia worldwide, manufacturers and high-end consulting firms. The company exports products to Europe and North America. MGC Pharmaceuticals is headquartered in Perth, Western Australia, Australia.
For a complete picture of (Cannabidiol + dronabinol)’s drug-specific PTSR and LoA scores, buy the report here.